AbbVie, Galapagos aim to beat Vertex in CF
This article was originally published in Scrip
Executive Summary
AbbVie has signed a $405m deal with Galapagos of Belgium which will see the two companies pool resources with the aim of developing a superior treatment for cystic fibrosis to Vertex Pharmaceuticals' Kalydeco (ivacaftor). More than a hundred staff from the two partners will work together to advance Galapagos's early-stage in-house research and develop CF transmembrane conductance regulator (CFTR) therapies.
You may also be interested in...
Vertex Cystic Fibrosis Forecast Brightens, With Gloomy Prospects For Competition
Vertex continued its growth story in cystic fibrosis during 2017. It also chose a pair of candidates for Phase III triple combination development, threatening to virtually seal off market entry to others.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.